BioSpace News Archive

Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib. The trial also met a key secondary endpoin

Company’s long-term care vaccination effort remains on track, with nearly two million doses administered to date

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3

Calyx, the eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced a valuable new partnership program for Clinical Research Organizations (CROs).

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors.

A new study from Germany offers yet more data to show that childcare facilities and elementary schools should remain open or re-open to full-time, in-person learning as quickly as possible, according to an accompanying editorial by Children’s Hospital Colorado Infectious Disease Specialist Sean T.

OrthoSpin Ltd. (“OrthoSpin”), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its second generation, robotic, digitally enabled external fixation system for orthopedic treatments.

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy™ (lonafarnib) in the United States.

Evozyne, LLC, a privately held molecular engineering technology company founded by life science innovator Paragon Biosciences, announced today the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”).

SQI Diagnostics Inc.(the “Company” or “SQI”) ( (TSXV: SQD); (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that patient enrollment began for the Company’s clinical study for its direct-to-consumer COVID-19 HOME Antibody Test